Infection with multidrug-resistant Campylobacter coli mimicking recurrence of carcinoid syndrome: a case report of a neuroendocrine tumor patient with repeated diarrhea by Heimo Lagler et al.
CASE REPORT Open Access
Infection with multidrug-resistant
Campylobacter coli mimicking recurrence
of carcinoid syndrome: a case report of a
neuroendocrine tumor patient with
repeated diarrhea
Heimo Lagler1, Barbara Kiesewetter2 and Markus Raderer2*
Abstract
Background: Campylobacteriosis caused by Gram-negative bacteria of the genus Campylobacter (mainly C. jejuni and C.
coli) is one of the most common gastrointestinal zoonotic infections with increased incidence in humans worldwide.
The typical symptoms are severe abdominal cramps, diarrhea and sometimes fever. The clinical course of Campylobacter
infection is mainly mild and after one week self-limiting, but can take several weeks in some rare cases. However,
patients with neuroendocrine tumors in the gastrointestinal tract, a neoplasm of enterochromaffin/neuroendocrine cell
origin, can develop severe diarrhea during progression of tumor growth caused by hormonal excess due to the tumor.
Both diseases have very similar clinical symptoms and this case report elaborates the differences. So far it is known in the
literature that the clinical symptoms of campylobacteriosis can mimic appendicitis or acute colitis of inflammatory bowel
disease but a mimicking of recurrence of carcinoid syndrome in a patient with neuroendocrine tumor is not reported.
Case presentation: A 72-year-old man with already diagnosed and treated metastatic neuroendocrine tumor of
the terminal ileum (G1 rated, Ki-67 index 1 %) was again suffering from increasing diarrhea, abdominal cramps
and weight lost. These symptoms were similar to the initial symptoms due to the tumor which improved at the
time after total resection of the primary in the terminal ileum and regular therapy with long-acting release depot
octreotide intramuscularly. As progression/tachyphylaxis in symptomatic patients with carcinoid syndrome
undergoing therapy, reassessment of disease and analysis of tumor markers was initiated, and the interval of
intramuscular injections was shortened. Radiological findings and tumor marker levels disclosed no evidence of
neuroendocrine tumor progression and the symptoms continued. After 4 weeks with symptoms the patient
developed additionally fever. Due to impaired renal function and elevated signs of systemic inflammation fluid
replacement and empiric antimicrobial therapy were started. At this time-point the first stool cultures were taken
which disclosed an infection with C. coli. The empiric antimicrobial therapy was stopped after five days because
of multidrug-resistant isolated strain. During the ongoing symptomatic therapy the patient becomes gradually
symptom-free 6 weeks later, resulting a total duration of symptoms caused by campylobacteriosis of 13 weeks.
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Conclusion: This case of infection with C. coli mimicking recurrence of carcinoid syndrome suggests that assessment
for bacterial gastrointestinal infections should be taken into account also in patients with neuroendocrine tumors who
present worsening of their symptoms in spite of initially successful management. The duration of symptoms caused by
campylobacteriosis were significantly extended which might be due to gastroenteric dysfunctions/mucosal changes
caused by the carcinoid syndrome in this patient.
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Background
Campylobacteriosis caused by Gram-negative bacteria of
the genus Campylobacter (mainly C. jejuni and C. coli)
is one of the most common gastrointestinal zoonotic in-
fection with increased incidence in humans in both de-
veloped and developing countries worldwide [1, 2]. The
source of infection is mainly contaminated food (par-
ticular undercooked poultry products, unpasteurized
milk or water) or a close contact to animals [2–4]. After
a short incubation period of few days, the typical clinical
symptoms with abrupt onset are severe abdominal
cramps associated with watery or bloody diarrhea with
8–10 bowel movements per day, weight loss and fever
[5]. Usually, the infection with Campylobacter is self-
limiting without any antimicrobial treatment and the
clinical symptoms resolved after a median duration of
6 days [3]. During the time of symptoms supportive
therapy like the maintenance of proper hydration and
correction of electrolyte abnormalities are sufficient. The
bacterial excretion takes 1–3 weeks, but can take several
weeks in some cases, chronic carriers are rarely found
and are mainly associated with immune deficiency [6, 7].
Patients with neuroendocrine tumors (NETs) in the
gastrointestinal tract, a neoplasm of enterochromaffin/
neuroendocrine cell origin, develop during progression
of tumor growth typically diarrhea and weight lost
caused by hormonal excess due to the tumor [8]. The
clinical symptoms of the first presentation or progres-
sion of a NET of the gastrointestinal tract are with ab-
dominal cramps, diarrhea and weight lost, similar to a
bacterial gastroenteritis like campylobacteriosis without
fever. Carcinoid syndrome is usually characterised by
watery diarrhea without relevant amounts of mucus and
blood, which differs sometimes from diarrhea caused by
bacterial pathogens like Campylobacter where blood and
mucus can be found in the diarrheal stool. It has already
been described that the clinical symptoms of campylo-
bacteriosis can mimic other diseases including acute ap-
pendicitis [9–11] or acute colitis of inflammatory bowel
disease [12]. However, in the literature no case of
campylobacteriosis mimicking clinical symptoms of a
progression of a metastatic neuroendocrine tumor of the
gastrointestinal tract is described.
Case presentation
A 72-year-old man with already diagnosed metastatic
NET and suffering from abdominal cramps, diarrhea and
weight loss since 3 weeks was referred at our outpatient
department. The NET had been located in the terminal
ileum and had been diagnosed from biopsy of multiple
liver metastases evidenced on CT-scanning nineteen
months ago. Before undergoing clinical work-up and
diagnosing the NET, the patient related an almost
12 month history of increasing diarrhea (up to 15 bowel
movements per day) with weight loss of 11 kg. The
tumor was rated G1 with a Ki-67-labeling index of 1 %
[13], and the primary in the terminal ileum was resected.
At diagnosis, the serum level of tumor marker chromo-
granin A was elevated at 1080 ng/ml (normal range
<100 ng/ml), and the urinary 5-hydroxyindoleacetic acid
(5-HIAA) was 29 mg/24 h (normal range 2 – 9 mg/
24 h). After perioperative prevention with short-acting
somatostatin (SST)-analogue octreotide subcutaneously,
the patient was put on long-acting release depot octreo-
tide LAR (OCT-LAR) 30 mg intramuscularly every
28 days, resulting in decrease of stool frequency to 2–3
bowel movements/day and weight gain by 7 kg.
Nineteen months after initiation of OCT-LAR, how-
ever, the patient again complained of severe diarrhea
with up to 10 bowel movements with weight loss of 4 kg
over 3 weeks. As progression/tachyphylaxis in symptom-
atic patients with carcinoid syndrome undergoing ther-
apy with SST-analogues, reassessment of disease status
performing a PET/CT with a SST receptor PET tracer
[68Ga-DOTA,1-Nal3]-octreotide (68Ga-DOTANOC) and
analysis of tumor markers was initiated, and the interval
of OCT-LAR intramuscular injections was shortened to
21 days. However, radiological findings disclosed no evi-
dence of NET progression. Also the regularly monitored
tumor marker levels of chromogranin A and serotonin
had been stable over the last months and were not indi-
cative of progression (chromogranin A: 215 ng/ml; nor-
mal range <100 ng/ml and serotonin: 394 ng/ml; normal
range 40–400 ng/ml). After 4 weeks with symptoms the
patient developed additional fever up to 39 °C and night
sweats for 2 days. Because of elevated signs of systemic
inflammation (CRP: 20 mg/dl; normal range <0.5 mg/dl)
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and acute renal failure (serum creatinine: 6.7 mg/dl; nor-
mal rage 0.7–1.2 mg/dl) the outpatients was hospitalized
and supportive therapy with intravenous hydration and
maintenance of electrolyte balance plus empiric anti-
microbial therapy with ciprofloxacin and metronidazole
was started. At this time-point the first stool cultures
were taken to identify microorganisms causing diarrhea like
Salmonella, Campylobacter, Shigella and Yersinia. Stool
samples were plated onto MacConkey agar (Oxoid, UK),
Hektoen agar (bioMérieux, France), Cefsulodin-Irgasan-
Novobiocin (CIN) agar (Becton Dickinson, Germany) and
Campylosel agar (bioMérieux, France) as well as inoculated
in Selenite F broth. All samples were incubated at 35–37 °C
for 24 h. Suspicious colonies growing on Campylosel agar
(a selective medium for the isolation of Campylobacter)
were identified using matrix-assisted laser desorption
ionization time-of-flight mass spectrometry (MALDI-TOF,
Bruker, Germany) as described by the manufacturer. The
result obtained by MALDI-TOF was consistent with the
presence of C. coli. The following antimicrobial susceptibil-
ity testing according to European Committee on Anti-
microbial Susceptibility Testing (EUCAST) disclosed a
multidrug-resistant (MDR) C. coli (resistant to all 3 anti-
microbial classes, the macrolides, fluoroquinolones and tet-
racyclines). Blood cultures and stool testing for Clostridium
difficile toxins were negative. In view of limited therapeutic
options due to the MDR and the usually self-limiting
nature of campylobacteriosis, the antimicrobial therapy
was stopped after 5 days and a wait and see approach
was chosen. The patient became symptom-free with
normalization of serial stool cultures 6 weeks later,
resulting in a total duration of symptoms of 13 weeks.
Conclusion
The clinical symptoms of Campylobacteriosis can mimic
not only appendicitis or acute colitis of inflammatory
bowel disease but also recurrence of carcinoid syndrome
in a patient with NET. In addition to the four most fre-
quent and harmful bacterial enteric pathogens Salmon-
ella, Campylobacter, Shigella and Yersinia tested by a
routine stool culture, also other bacteria like Clostridium
difficile and enteropathogenic Vibrio species or Escheri-
chia coli strains could cause similar clinical symptoms.
However, if bacterial stool examinations are negative,
additional virological analyses for example for detecting
cytomegaly virus (CMV) and parasitological analysis for
example for detecting Entamoeba histolytica or Giardia
lamblia in the stool should be considered.
Interestingly this patient developed mainly watery
diarrhea with a little mucus but without blood. However,
the clinical symptoms with abdominal cramps caused by
C. coli were very similar to the symptoms caused by the
NET and therefore the infection was remaining undiag-
nosed for weeks. The duration of 13 weeks of symptoms
caused by Campylobacter was remarkably extended,
which might be due to gastroenteric dysfunctions or
mucosal changes caused by the carcinoid syndrome.
This case of infection with C. coli mimicking recur-
rence of carcinoid syndrome suggests that assessment
for bacterial gastrointestinal infections should be taken
into account also in patients with NETs who present
worsening of their symptoms in spite of initially success-
ful management.
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